Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Smith

Showing results (21-30 of 150) with videos related to

Pageof 15
Sort By:
Journal of the American Academy of Dermatology|March 17, 2016
"Pretend you didn't hear that"--managing ethical dilemmas from the bottom of a medical hierarchyRobert J Smith, Jules B Lipoff
Metabolic Syndrome and Related Disorders|November 23, 2011
The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease riskAbayomi O Akanji, Robert J Smith
BMC Infectious Diseases|January 13, 2010
Modelling imperfect adherence to HIV induction therapyRachelle E Miron, Robert J Smith
Pain Management|August 7, 2015
Engaging patients around the risks of opioid misuse in the emergency departmentZachary F Meisel, Robert J Smith
Endocrinology|July 23, 2005
The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signalingAimee M Dufresne, Robert J Smith
Bulletin of Mathematical Biology|November 7, 2013
Resistance to protease inhibitors in a model of HIV-1 infection with impulsive drug effectsRachelle E Miron, Robert J Smith
Trends in Molecular Medicine|July 5, 2015
Harnessing the crowd to accelerate molecular medicine researchRobert J Smith, Raina M Merchant
Mathematical Biosciences|March 25, 2008
Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?Robert J Smith, Elissa J Schwartz
JAMA Internal Medicine|May 8, 2013
Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorderRobert J Smith, William R Hiatt
The Lancet. Infectious Diseases|September 29, 2004
Could disease-modifying HIV vaccines cause population-level perversity?Robert J Smith, Sally M Blower
Pageof 15

Showing results (21-30 of 150) with videos related to

Sort By:
Pageof 15
Journal of the American Academy of Dermatology|March 17, 2016
"Pretend you didn't hear that"--managing ethical dilemmas from the bottom of a medical hierarchyRobert J Smith, Jules B Lipoff
Metabolic Syndrome and Related Disorders|November 23, 2011
The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease riskAbayomi O Akanji, Robert J Smith
BMC Infectious Diseases|January 13, 2010
Modelling imperfect adherence to HIV induction therapyRachelle E Miron, Robert J Smith
Pain Management|August 7, 2015
Engaging patients around the risks of opioid misuse in the emergency departmentZachary F Meisel, Robert J Smith
Endocrinology|July 23, 2005
The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signalingAimee M Dufresne, Robert J Smith
Bulletin of Mathematical Biology|November 7, 2013
Resistance to protease inhibitors in a model of HIV-1 infection with impulsive drug effectsRachelle E Miron, Robert J Smith
Trends in Molecular Medicine|July 5, 2015
Harnessing the crowd to accelerate molecular medicine researchRobert J Smith, Raina M Merchant
Mathematical Biosciences|March 25, 2008
Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?Robert J Smith, Elissa J Schwartz
JAMA Internal Medicine|May 8, 2013
Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorderRobert J Smith, William R Hiatt
The Lancet. Infectious Diseases|September 29, 2004
Could disease-modifying HIV vaccines cause population-level perversity?Robert J Smith, Sally M Blower
Pageof 15